HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nu-Man Tsai Selected Research

butylidenephthalide

1/2021Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation of n-butylidenephthalide in breast cancer cells.
1/2021Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma.
5/2020Antitumor Effects of N-Butylidenephthalide Encapsulated in Lipopolyplexs in Colorectal Cancer Cells.
1/2020Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood-Brain Barrier and Suppresses Growth of Glioblastoma.
12/2018Antitumor Effect of n-Butylidenephthalide Encapsulated on B16/F10 Melanoma Cells In Vitro with a Polycationic Liposome Containing PEI and Polyethylene Glycol Complex.
1/2015Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.
11/2006The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nu-Man Tsai Research Topics

Disease

33Neoplasms (Cancer)
06/2021 - 08/2004
6Brain Neoplasms (Brain Tumor)
01/2021 - 05/2005
6Glioblastoma (Glioblastoma Multiforme)
01/2021 - 05/2005
5Melanoma (Melanoma, Malignant)
02/2021 - 09/2017
4Hepatocellular Carcinoma (Hepatoma)
01/2021 - 05/2020
4Neoplasm Metastasis (Metastasis)
01/2021 - 02/2010
3Body Weight (Weight, Body)
01/2021 - 01/2018
3Breast Neoplasms (Breast Cancer)
01/2021 - 02/2016
3Hypoxia (Hypoxemia)
01/2018 - 09/2007
2Mouth Neoplasms (Oral Cancer)
06/2020 - 01/2020
2Neurodegenerative Diseases (Neurodegenerative Disease)
01/2018 - 01/2014
2Stomach Neoplasms (Stomach Cancer)
06/2010 - 02/2010
2Carcinogenesis
02/2010 - 01/2002
2Lung Neoplasms (Lung Cancer)
11/2007 - 07/2006
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2021
1Triple Negative Breast Neoplasms
01/2021
1Leukemia
11/2020
1Colonic Neoplasms (Colon Cancer)
05/2020
1Colorectal Neoplasms (Colorectal Cancer)
05/2020
1Neuroblastoma
01/2020
1Anemia
12/2018
1Glioma (Gliomas)
01/2018
1Dementia (Dementias)
01/2018
1Chronic Disease (Chronic Diseases)
05/2016
1Glomerulonephritis
01/2013

Drug/Important Bio-Agent (IBA)

14Pharmaceutical PreparationsIBA
01/2021 - 11/2006
11Proteins (Proteins, Gene)FDA Link
02/2021 - 02/2010
7butylidenephthalideIBA
01/2021 - 11/2006
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 11/2010
4Antineoplastic Agents (Antineoplastics)IBA
06/2021 - 07/2006
3poly(ethylene glycol)-co-poly(ethyleneimine)IBA
01/2021 - 02/2019
3Liposomes (Liposome)IBA
01/2021 - 12/2018
3Cisplatin (Platino)FDA LinkGeneric
01/2021 - 01/2018
3Therapeutic UsesIBA
01/2020 - 05/2011
2cedrolIBA
12/2020 - 10/2020
2Proliferating Cell Nuclear Antigen (PCNA)IBA
10/2020 - 01/2018
2Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
05/2020 - 12/2018
2PolyethyleneimineIBA
05/2020 - 12/2018
2Adenosine Triphosphate (ATP)IBA
11/2016 - 05/2002
2LignansIBA
11/2016 - 11/2007
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2011 - 11/2010
2CarcinogensIBA
06/2010 - 02/2010
2Chaperonin 60IBA
06/2010 - 02/2010
2isochaihulactoneIBA
11/2007 - 07/2006
2AcetoneIBA
07/2006 - 08/2004
1PolyaminesIBA
02/2021
1Adenosine Monophosphate (AMP)IBA
02/2021
1BromidesIBA
02/2021
1isoamylamineIBA
02/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021
1Apoptosis Regulatory ProteinsIBA
01/2021
1Kynurenine 3-Monooxygenase (Kynurenine 3 Monooxygenase)IBA
01/2021
1Cell Cycle ProteinsIBA
01/2021
1Eosine Yellowish-(YS) (Eosin)IBA
01/2021
1Hematoxylin (Haematoxylon)IBA
01/2021
1Androgen Receptors (Androgen Receptor)IBA
12/2020
1Volatile Oils (Essential Oils)IBA
11/2020
1Caspase 3 (Caspase-3)IBA
10/2020
1CaspasesIBA
06/2020
1Drug CarriersIBA
05/2020
1Cytotoxins (Cytolysins)IBA
05/2020
1Immunoglobulin G (IgG)IBA
04/2020
1Fluorouracil (Carac)FDA LinkGeneric
01/2020
1Neoplasm AntibodiesIBA
02/2019
1Trastuzumab (Herceptin)FDA Link
02/2019
1Epidermal Growth Factor (EGF)IBA
02/2019
1LactamsIBA
01/2018
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
01/2018
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2018
1SynucleinsIBA
01/2018
1Ceftriaxone (Ceftriaxon)FDA LinkGeneric
01/2018
1Anti-Bacterial Agents (Antibiotics)IBA
01/2018
1thiazolyl blueIBA
01/2018
1Temozolomide (Temodar)FDA LinkGeneric
01/2018
1Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA
01/2018
1Glutamic Acid (Glutamate)FDA Link
01/2018
1Actins (F Actin)IBA
09/2017
1Surface Antigens (Surface Antigen)IBA
11/2016
1AutoantibodiesIBA
11/2016
1AntibodiesIBA
11/2016
1Endoplasmic Reticulum Chaperone BiPIBA
11/2016
1Masoprocol (Actinex)FDA Link
11/2016
1Glucose (Dextrose)FDA LinkGeneric
11/2016
1Lipid NanoparticlesIBA
05/2016
1Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)IBA
05/2016
1ChitosanIBA
05/2016
1TamoxifenFDA LinkGeneric
02/2016
1Estrogen ReceptorsIBA
02/2016
1Fluorescent Dyes (Fluorescent Probes)IBA
02/2016
1Methanol (Carbinol)IBA
01/2013
1CurcuminIBA
04/2012

Therapy/Procedure

15Therapeutics
06/2021 - 11/2010
5Drug Therapy (Chemotherapy)
02/2021 - 01/2013
4Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2020 - 05/2005
2Aftercare (After-Treatment)
01/2021 - 12/2018
1Radiotherapy
02/2021
1Subcutaneous Injections
01/2018
1Chemoprevention
09/2017
1Oral Administration
05/2016
1Intravenous Administration
01/2015